- Home
- NBIS vs STVN Comparison
NBIS vs STVN Comparison
Compare NBIS & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIS
- STVN
- Stock Information
- Founded
- NBIS 2000
- STVN 1949
- Country
- NBIS Netherlands
- STVN Italy
- Employees
- NBIS N/A
- STVN N/A
- Industry
- NBIS
- STVN Containers/Packaging
- Sector
- NBIS
- STVN Consumer Discretionary
- Exchange
- NBIS NYSE
- STVN Nasdaq
- Market Cap
- NBIS 5.5B
- STVN 6.2B
- IPO Year
- NBIS 2011
- STVN 2021
- Fundamental
- Price
- NBIS $39.84
- STVN $20.84
- Analyst Decision
- NBIS Strong Buy
- STVN Buy
- Analyst Count
- NBIS 1
- STVN 6
- Target Price
- NBIS $51.00
- STVN $27.50
- AVG Volume (30 Days)
- NBIS 17.4M
- STVN 365.0K
- Earning Date
- NBIS 02-20-2025
- STVN 03-06-2025
- Dividend Yield
- NBIS N/A
- STVN 0.28%
- EPS Growth
- NBIS N/A
- STVN N/A
- EPS
- NBIS N/A
- STVN 0.48
- Revenue
- NBIS $117,500,000.00
- STVN $1,220,254,294.00
- Revenue This Year
- NBIS $60.56
- STVN N/A
- Revenue Next Year
- NBIS $400.27
- STVN N/A
- P/E Ratio
- NBIS N/A
- STVN $43.99
- Revenue Growth
- NBIS N/A
- STVN 3.53
- 52 Week Low
- NBIS $14.09
- STVN $16.56
- 52 Week High
- NBIS $50.87
- STVN $34.00
- Technical
- Relative Strength Index (RSI)
- NBIS N/A
- STVN 47.73
- Support Level
- NBIS N/A
- STVN $18.37
- Resistance Level
- NBIS N/A
- STVN $20.38
- Average True Range (ATR)
- NBIS 0.00
- STVN 1.24
- MACD
- NBIS 0.00
- STVN -0.07
- Stochastic Oscillator
- NBIS 0.00
- STVN 54.53
About NBIS NEBIUS GROUP N V
Nebius Group NV is a tech company. It is a European provider of infrastructure and services to AI builders globally. The group builds full-stack infrastructure to service the growth of the AI industry, including the scale of GPU clusters, cloud platforms, tools, and services for developers. It has R&D hubs across Europe, North America and Israel.
About STVN Stevanato Group S.p.A.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.